M-CAP eliminates a majority of variants of uncertain significance in clinical exomes at high sensitivity
Nature genetics, 2016•nature.com
Variant pathogenicity classifiers such as SIFT, PolyPhen-2, CADD, and MetaLR assist in
interpretation of the hundreds of rare, missense variants in the typical patient genome by
deprioritizing some variants as likely benign. These widely used methods misclassify 26 to
38% of known pathogenic mutations, which could lead to missed diagnoses if the classifiers
are trusted as definitive in a clinical setting. We developed M-CAP, a clinical pathogenicity
classifier that outperforms existing methods at all thresholds and correctly dismisses 60% of …
interpretation of the hundreds of rare, missense variants in the typical patient genome by
deprioritizing some variants as likely benign. These widely used methods misclassify 26 to
38% of known pathogenic mutations, which could lead to missed diagnoses if the classifiers
are trusted as definitive in a clinical setting. We developed M-CAP, a clinical pathogenicity
classifier that outperforms existing methods at all thresholds and correctly dismisses 60% of …
Abstract
Variant pathogenicity classifiers such as SIFT, PolyPhen-2, CADD, and MetaLR assist in interpretation of the hundreds of rare, missense variants in the typical patient genome by deprioritizing some variants as likely benign. These widely used methods misclassify 26 to 38% of known pathogenic mutations, which could lead to missed diagnoses if the classifiers are trusted as definitive in a clinical setting. We developed M-CAP, a clinical pathogenicity classifier that outperforms existing methods at all thresholds and correctly dismisses 60% of rare, missense variants of uncertain significance in a typical genome at 95% sensitivity.
nature.com